이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Ketosis, Immune Function and Metabolic Adaptation in Response to Short-term Fasting in Critical Illness (KETO-FAST)

2026년 8월 28일 업데이트: Martin Sundstrom Rehal, Karolinska University Hospital

KETOsis, Immune Function and Metabolic Adaptation in Response to Short-Term Fasting in Critical Illness (KETO-FAST): A Translational Substudy of the FAST-ICU Cluster-randomized Cross-over Trial.

KETO-FAST is a pre-planned translational substudy of the FAST-ICU cluster-randomized cross-over trial. The substudy will characterize ketone body production and associated metabolic, autophagy-related, and immune cellular responses during the first 72 hours after intensive care unit admission in critically ill patients exposed to delayed nutrition compared with patients receiving standard care.

Patients enrolled in FAST-ICU at designated participating centers will undergo serial blood sampling during the first 72 hours after ICU admission. Plasma ketone body concentrations, targeted metabolomics, serum-induced cellular responses in vitro, leukocyte autophagy markers, and immune cell phenotypes and functional markers will be assessed. In addition, 10 healthy volunteers will perform a 72-hour fast with blood sampling to provide reference values from non-critically ill subjects.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

Early nutrition during critical illness remains controversial. Large randomized trials in intensive care unit patients have found no clear benefit and possible harm from full early feeding, while current guidelines recommend early hypocaloric nutrition. However, high-quality evidence comparing early hypocaloric nutrition with complete withholding of nutrition during the first days of critical illness is limited.

In healthy humans, short-term starvation induces ketone body production through fatty acid oxidation. Ketone bodies such as β-hydroxybutyrate and acetoacetate are energy substrates for organs including the heart and brain and may also act as signaling molecules involved in autophagy, mitochondrial metabolism, and immune function. In critical illness, however, the normal fasting response may be altered by stress metabolism, inflammation, insulin administration, corticosteroids, and organ dysfunction. The extent to which critically ill patients develop clinically relevant ketosis during short-term fasting remains uncertain.

The parent FAST-ICU trial is a cluster-randomized cross-over trial comparing two ICU nutrition strategies during the first 72 hours after ICU admission: delayed nutrition with no enteral or parenteral nutrition and no glucose-containing maintenance fluids, versus standard care including early enteral nutrition and maintenance glucose according to local practice. KETO-FAST uses this randomized exposure to study the biological response to short-term fasting in critically ill patients.

The primary objective of KETO-FAST is to compare plasma ketone body concentrations during the first 72 hours after ICU admission between patients exposed to delayed nutrition and patients receiving standard care. Secondary and exploratory objectives are to characterize associated changes in targeted metabolic pathways, serum-mediated cellular responses, leukocyte autophagy markers, and immune cell phenotypes and functional markers.

연구 유형

중재적

등록 (추정된)

200

단계

해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

이름: Martin Sundström Rehal, MD PhD
전화번호: +46-8-12381507
이메일: martin.sundstrom-rehal@regionstockholm.se

연구 장소

스웨덴
- - Stockholm, 스웨덴, 14186
    - Karolinska University Hospital Huddinge
    - 연락하다:
      
      Martin Sundström Rehal, MD PhD
      
      전화번호: +46812381507
      
      이메일: martin.sundstrom-rehal@regionstockholm.se

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

성인
고령자

건강한 자원 봉사자를 받아들입니다

예

설명

Inclusion Criteria:

Adult (≥18 years).
ICU admission (index admission to the participating ICU).

Exclusion Criteria:

The patient requires intravenous glucose infusion, enteral nutrition or parenteral nutrition according to the attending clinician's assessment,
Acute or acute-on-chronic liver failure
Moderate hypernatremia ( >150 mmol/L)
Diabetic ketoacidosis or hyperosmolar hyperglycemic state at admission,
Pregnancy,
Exclusive end-of-life care (no other treatment goal than comfort care for end of life),
Organ donor,
Prior enrolment in this trial during the same hospitalisation,
Patients with a metabolic disease requiring specific diet and patients with clinical need for a ketogenic diet.
Patients already enrolled in other interventional studies on nutrition, intravenous fluids, phosphate supplementation or hormonal therapies that influence glucose homeostasis.
Inclusion not possible due to site-specific regulatory issues regarding the ethical approval or informed consent procedure.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

주 목적: 치료
할당: 무작위
중재 모델: 크로스오버 할당
마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔 참가자 그룹 / 팔 시험 프로토콜에 따라 특정 중재/치료를 받거나 중재를 받지 않는 임상 시험 참가자 그룹 또는 하위 그룹입니다.	개입 / 치료 개입 / 치료 임상 연구의 초점이 되는 프로세스 또는 작업입니다. 개입에는 약물, 의료 기기, 절차, 백신 및 조사 중이거나 이미 사용 가능한 기타 제품이 포함됩니다. 개입에는 교육이나 식이요법 및 운동 수정과 같은 비침습적 접근법도 포함될 수 있습니다.
실험적: Intervention Intensive care unit patients with policy allocation to delayed medical nutrition therapy in main study: no enteral nutrition, parenteral nutrition or maintenance glucose solutions for first 72 hours.	다른: Delayed nutrition Intervention Policy (A): Withhold nutrition and glucose solutions (First 72 h) No enteral nutrition (EN) and no parenteral nutrition (PN) for the first 72 hours from ICU admission time (t=0). No glucose-containing maintenance IV solutions during the first 72 hours. Balanced crystalloids or normal saline permitted per clinical need. 5% glucose solution permitted as vehicle for IV medications as necessary (according to local standard), or as treatment for hypernatremia Oral intake permitted ad lib if the patient is awake, willing and able to eat safely. Micronutrients: daily vitamins and trace elements are allowed per local practice. Protein supplements are not allowed unless part of the standard oral diet. Arterial or venous blood glucose measurement every 4h. Rescue glucose will be administered according to local protocol. After 72 hours, feeding transitions to usual care at clinician discretion (including EN/PN initiation and caloric/protein targets).
활성 비교기: Control Intensive care unit patients with policy allocation to standard care in main study: nutritional management according to regular unit protocols.	다른: Standard nutrition Control Policy (B): Standard of Care Initiation and advancement of EN/PN and use of glucose-containing maintenance fluids per local practice from admission. Arterial or venous blood glucose measurement every 4h. Insulin and glycaemic control per local protocols.
활성 비교기: Healthy reference controls Healthy subjects undergoing 72 hour fast with same blood sampling procedure as in ICU.	다른: Fasting 72-hour fasting period with water and non-caloric beverages.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정	측정값 설명	기간
Between-group differences over time in plasma β-hydroxybutyrate and acetoacetate concentrations during the first 72 hours after ICU admission 기간: From ICU admission and up to 72 hours after ICU admission, using serial daily blood samples	Plasma β-hydroxybutyrate and acetoacetate concentrations will be measured in mmol/L in serial blood samples collected from ICU admission through 72 hours after admission. Cumulative concentrations of ketone bodies will be compared between the delayed-nutrition and standard-care groups over the measurement period. Results will be reported as between-group effect estimates over time, with 95% confidence intervals.	From ICU admission and up to 72 hours after ICU admission, using serial daily blood samples

2차 결과 측정

결과 측정	측정값 설명	기간
Between-group difference in serum-induced autophagy flux in cultured cells 기간: Single serum sample collected on ICU day 3 or 4, depending on the time of ICU admission	Cultured cells will be incubated with serum collected from substudy participants. Autophagy flux will be quantified using prespecified cellular autophagy markers under paired conditions with and without pharmacological inhibition of lysosomal degradation. The resulting normalized autophagy-flux measure will be compared between the delayed-nutrition and standard-care groups and reported as a between-group effect estimate with a 95% confidence interval.	Single serum sample collected on ICU day 3 or 4, depending on the time of ICU admission
Between-group difference in normalized relative abundance of autophagy-related proteins in peripheral blood leukocytes assessed by Western blotting 기간: Single final substudy sample collected on ICU day 3 or 4, depending on the time of ICU admission	The relative abundance of prespecified autophagy-related proteins will be quantified in isolated peripheral blood leukocytes by Western blot densitometry and normalized to an appropriate loading control. For each protein marker, and for derived protein ratios where applicable, normalized values will be compared between the randomized groups and reported as a between-group effect estimate with a 95% confidence interval.	Single final substudy sample collected on ICU day 3 or 4, depending on the time of ICU admission
Between-group differences in frequencies of major peripheral blood immune-cell subsets assessed by multiparameter flow cytometry 기간: Single final substudy sample collected on ICU day 3 or 4, depending on the time of ICU admission	Multiparameter flow cytometry will be used to identify and quantify prespecified major immune-cell populations and phenotypic subsets relevant to critical illness and nutrient deprivation. Each subset will primarily be expressed as a percentage of its relevant parent cell population. Subset frequencies will be compared between the delayed-nutrition and standard-care groups and reported as between-group effect estimates with 95% confidence intervals.	Single final substudy sample collected on ICU day 3 or 4, depending on the time of ICU admission
Between-group differences in immune-cell phenotypes and marker expression assessed by multiparameter flow cytometry 기간: Single final substudy sample collected on ICU day 3 or 4, depending on the time of ICU admission	Prespecified peripheral blood immune-cell populations will be characterized by multiparameter flow cytometry. Outcomes will include the frequency of cell populations expressing markers related to immune activation, exhaustion or immune-checkpoint signalling, cellular metabolic state, and functional capacity, together with marker-expression intensity where applicable. Results for each prespecified cell population and marker will be compared between the delayed-nutrition and standard-care groups and reported as between-group effect estimates with 95% confidence intervals.	Single final substudy sample collected on ICU day 3 or 4, depending on the time of ICU admission
Between-group difference in normalized expression of prespecified autophagy-related genes in peripheral whole blood on ICU day 3 or 4, assessed by RNA sequencing 기간: Single blood sample collected on ICU day 3 or 4, depending on the time of ICU admission	RNA will be extracted from peripheral whole blood collected in EDTA tubes on ICU day 3 or 4. Expression of prespecified autophagy-related genes will be quantified using RNA sequencing and compared between the randomized groups. For each gene, the treatment effect will be reported as the between-group log2 fold change with a 95% confidence interval and a false-discovery-rate-adjusted P value.	Single blood sample collected on ICU day 3 or 4, depending on the time of ICU admission
Between-group differences in plasma concentrations of prespecified metabolites and pathway-level metabolomic measures during the first 72 hours after ICU admission 기간: From ICU admission and up to 72 hours after ICU admission, using serial daily blood samples	Targeted metabolomic analysis will quantify prespecified plasma metabolites related to metabolic pathways relevant to fasting and critical illness, including ketogenesis, fatty acid metabolism, amino acid metabolism, glycolysis, and the tricarboxylic acid cycle. Individual metabolite concentrations and predefined pathway-level summary measures, where applicable, will be compared between the delayed-nutrition and standard-care groups across the first 72 hours after ICU admission. Results will be reported as between-group effect estimates with 95% confidence intervals.	From ICU admission and up to 72 hours after ICU admission, using serial daily blood samples

기타 결과 측정

결과 측정	측정값 설명	기간
Between-group differences in point-of-care whole-blood β-hydroxybutyrate concentration during the first 72 hours after ICU admission 기간: From ICU admission and up to 72 hours after ICU admission, using serial daily blood samples	Whole-blood β-hydroxybutyrate concentration will be measured in mmol/L using a point-of-care ketone analyzer at participating sites where this measurement is available. Measurements obtained from ICU admission through 72 hours will be compared between the delayed-nutrition and standard-care groups. Results will be reported for individual sampling time points and as an overall between-group effect across the measurement period, with 95% confidence intervals.	From ICU admission and up to 72 hours after ICU admission, using serial daily blood samples

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Karolinska University Hospital

협력자

Tartu University Hospital

수사관

연구 의자: Olav Rooyackers, PhD, Karolinska University Hospital/Karolinska Institute
수석 연구원: Martin Sundström Rehal, MD PhD, Karolinska University Hospital/Karolinska Institutet

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 8월 31일

기본 완료 (추정된)

2027년 7월 31일

연구 완료 (추정된)

2027년 7월 31일

연구 등록 날짜

최초 제출

2026년 7월 13일

QC 기준을 충족하는 최초 제출

2026년 7월 29일

처음 게시됨 (실제)

2026년 7월 31일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 1일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 8월 28일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

K 2026-5194
ISRCTN16339579 (레지스트리 식별자: ISRCTN)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

De-identified individual participant data may be made available after publication of the main substudy results upon reasonable request and according to applicable ethical approvals, data protection regulations, biobanking regulations, and material transfer agreements. Omics data sharing will be governed by participant consent, ethical approval, and applicable data protection requirements.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

Ketosis, Immune Function and Metabolic Adaptation in Response to Short-term Fasting in Critical Illness (KETO-FAST)